Skip to main content
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. — Investor Relations & Filings

Ticker · EWTX ISIN · US28036F1057 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2024-05-10 Capital/Financing Update
Country US United States of America
Listing US EWTX

About Edgewise Therapeutics, Inc.

https://edgewisetx.com/

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for severe and rare muscle disorders. The company leverages its expertise in muscle science to create precision medicines for conditions including muscular dystrophies and serious cardiac diseases. Its primary goal is to develop treatments that address the underlying causes of these debilitating conditions to improve the lives of patients and their families.

Recent filings

Filing Released Lang Actions
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the SEC, which is a type of capital markets filing used to register securities for public offering. It includes a base prospectus and a sales agreement prospectus supplement describing the offering of common stock, preferred stock, debt securities, and other instruments. The document is not an annual report, earnings release, or management discussion, but rather a detailed registration statement for capital raising purposes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2024-05-10 English
FORM S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes detailed legal and regulatory information about the registration, indemnification provisions, incorporation by reference of other filings, and exhibits related to the securities offering. This type of filing is specifically related to capital raising activities through employee stock plans and is not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update filings.
2024-05-09 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-09 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2024, by Edgewise Therapeutics, Inc. It announces the issuance of a press release regarding financial results for the first quarter ended March 31, 2024. The document states that the full text of the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a current report announcing the event and providing the press release. Given the short length (3789 characters) and the nature of the content as an announcement of financial results rather than the results themselves, this fits the category of a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR).
2024-05-09 English
PRIMARY DOCUMENT
Director's Dealing
2024-05-08 English
PRIMARY DOCUMENT
Director's Dealing
2024-05-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.